
|Articles|May 13, 2015
- NSCLC (Issue 7)
- Volume 7
- Issue 2
Combining Bevacizumab With EGFR TKIs in Lung Cancer
Author(s)Edward S. Kim, MD
Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses combining bevacizumab with EGFR tyrosine kinase inhibitors (TKI) in the treatment of lung cancer.
Advertisement
Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses combining bevacizumab with EGFR tyrosine kinase inhibitors (TKI) in the treatment of lung cancer.
<<<
Articles in this issue
over 10 years ago
MET as a Secondary Driver in Lung Cancerover 10 years ago
MiR-34a Link to PD-L1 May Mean New Immunotherapy in NSCLCover 10 years ago
More Endpoints Not Necessarily Merrier in NSCLC Drug Trialsover 10 years ago
Characteristics of Additional KRAS Subsets in Lung Cancerover 10 years ago
US-Cuban Partnership Developing Anticancer Vaccine for NSCLCAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















